Inactive Instrument

Antibe Therapeutics Inc.

Equities

ATE

CA0370255097

Biotechnology & Medical Research

Antibe Therapeutics Inc. Appoints Jeremy Grushcow to the Part-Time Role of VP Legal and Strategy

October 22, 2013 at 05:53 pm

Antibe Therapeutics Inc. announced that Jeremy Grushcow, Ph.D., J.D. has been appointed to the part-time role of VP Legal and Strategy. He is endorsed by PLC for his corporate and commercial expertise in Life Sciences, and is recognized for his transactional expertise in the 2013 edition of The International Who's Who of Life Sciences Lawyers.

Latest news about Antibe Therapeutics Inc.

Antibe Therapeutics Inc. Announces Board Resignations	04-24	CI
Antibe Therapeutics Seeks Extension of Stay of Proceedings	04-19	MT
Antibe Therapeutics Says the TSX Reviewing a Potential Delisting of its Shares	04-16	MT
Antibe Therapeutics Brief: Announcing TSX Delisting Review	04-16	MT
Antibe Therapeutics Brief: Says To File an Application for an Initial Order Under Companies' Creditors Arrangement Act	04-09	MT
Antibe Therapeutics Inc. Announces Board Resignations	04-09	CI
Toronto Stocks Edge Lower; Ballard Power Rises on Fuel-Cell Order	04-01	DJ
Antibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. Regulator	04-01	DJ
Antibe Therapeutics Brief: Down More Than 50% After Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	04-01	MT
Antibe Therapeutics Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	04-01	MT
Antibe Therapeutics Brief: Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	04-01	MT
Antibe Therapeutics Inc. Announces FDA Clinical Hold on Otenaproxesul	04-01	CI
Antibe Therapeutics Inc. Announces Formation of Executive Committee	04-01	CI
Antibe Therapeutics Brief: Says to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting	03-20	MT
Antibe Therapeutics Brief: To Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting Tomorrow	03-07	MT
Antibe Therapeutics Announces Unfavorable Decision in Arbitration With Nuance Pharma	03-04	MT
Antibe Reported Q3 2024 Interim Financial and Operating Results	02-14	MT
Antibe Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Antibe Extending Early Warrant Exercise Incentive Program	02-01	MT
Antibe Therapeutics Announced Early Warrant Exercise Incentive Program	12-29	MT
Antibe Therapeutics Up 4% After Announcing Amendment To Warrant Extension, Price Changes	12-12	MT
Antibe Therapeutics Reports Q3 2023 Net and Comprehensive Loss of $5 Million	11-13	MT
Antibe Therapeutics Brief: For Quarter ended September 30, 2023, Net Loss and Comprehensive Loss totaled $5.0 million ($0.10 per share)	11-13	MT
Antibe Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-13	CI
Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul?s New Formulation	11-09	CI

Chart Antibe Therapeutics Inc.

Duration

Period

More charts

Company Profile

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Companyâs pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

Sector

Biotechnology & Medical Research

Calendar

2024-06-26 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.93%	124B
REGENERON PHARMACEUTICALS, INC.	+17.01%	109B
BIONTECH SE	-7.23%	23.84B
ARGENX SE	+1.98%	22.42B
GENMAB A/S	-14.29%	17.5B
BEIGENE, LTD.	-6.79%	16.61B
WUXI APPTEC CO., LTD.	-37.63%	16.43B
NEUROCRINE BIOSCIENCES, INC.	+2.17%	13.4B
SAREPTA THERAPEUTICS, INC.	+24.42%	11.47B

Bio Therapeutic Drugs